Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers

Patent metadata

Field	Value
Publication number	US-10775385-B2
Application number	US-201515736614-A
Country	US
Kind code	B2
Filing date	Oct 22, 2015
Priority date	Jun 18, 2015
Publication date	Sep 15, 2020
Grant date	Sep 15, 2020

Abstract

A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

First claim

The invention claimed is:

1. A method of treating one or more of autoimmune and inflammatory disorders, said method comprising administering to a patient in need thereof an asymmetrical TNFα trimer of a protein subunit comprising the amino-acid sequence of SEQ ID NO: 36, or corresponding sequence, wherein said TNFα trimer adopts a conformation when contacted with a compound that is capable of binding to the TNFα trimer to stabilize its asymmetric conformation, when determined by x-ray crystallography, with the Cα atoms of residues 12-18, 47-50, 54-64, 76-82, 91-97, 117-125, 129-137, and 150-156 of SEQ ID NO: 36, or corresponding sequence, for all subunits within 0.9 Å RMSD of the same atoms of the Reference Structure Compound34.pdb, said TNF-α trimer being able to bind TNFR1, but wherein signalling from said bound TNFR1 is attenuated or antagonised.

2. The method of claim 1 , wherein:
(a) the RMSD is within 0.85, 0.8, 0.7, 0.65, 0.6, 0.5, or 0.47 Å;
(b) the protein subunit comprises or consists of the amino-acid sequence of SEQ ID NO: 36; or
(c) the conformation is obtainable or obtained through the TNFα trimer forming a complex with any one of Compounds (1)-(64).

3. The method of claim 1 , wherein:
(a) the TNFα trimer antagonises the signalling of the TNFR1 receptor;
(b) the TNFα trimer has increased stability compared to the stability of a symmetrical TNFα trimer; or
(c) the TNFα trimer has increased stability compared to the stability of a symmetrical TNFα trimer and the increase in stability results in an increase in the thermal transition midpoint (T m ) of the TNFα trimer of at least 1° C., of at least 10° C., or is between 10° C. and 20° C.

4. The method of claim 1 , wherein:
(a) the TNFα trimer has an increased binding affinity to the TNFR1 receptor compared to the binding affinity of a symmetrical TNFα trimer to the TNFR1 receptor;
(b) the TNFα trimer has an increased binding affinity to the TNFR1 receptor compared to the binding affinity of a symmetrical TNFα trimer to the TNFR1 receptor and the TNFα trimer has an increased binding affinity to the TNFR1 receptor by increasing the on rate (k on-r ) and/or decreasing the off rate (k off-r ) compared to the k on-r and k off-r values for binding of the symmetrical TNFα trimer to the TNFR1 receptor;
(c) the TNFα trimer has an increased binding affinity to the TNFR1 receptor compared to the binding affinity of a symmetrical TNFα trimer to the TNFR1 receptor and the TNFα trimer.

Assignees

• Ucb Biopharma Sprl
• UCB Biopharma SRL

Inventors

• O'Connell James Philip
• Porter John Robert
• Lawson Alastair
• Kroeplien Boris
• Rapecki Stephen Edward
• Norman Timothy John
• Warrellow Graham John
• Arakaki Tracy Lynn
• Burgin Alex Buntin
• Pitt William Ross
• Calmiano Mark Daniel
• Schubert David Andreas
• Lightwood Daniel John
• Wootton Rebecca Jayne

Classifications

• G01N2500/04

  Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title

• G01N2333/7151

  for tumor necrosis factor [TNF]; for lymphotoxin [LT] · CPC title

• G01N2333/525

  Tumor necrosis factor [TNF] · CPC title

• G01N33/6863

  Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title